Immunovant Inc Stock News

NEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported financial results for its fiscal third quarter ended December 31, 2024.

NEW YORK , Jan. 24, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Immunovant, Inc. (NASDAQ: IMVT) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.

The year started off slow as far as insider purchases go.

Immunovant aims to initiate a pivotal registration study for IMVT-1402 targeting Graves' Disease by the end of 2024, with 4–5 trials in other IgG-mediated autoimmune disorders by March 2025. IMVT-1402 offers deeper IgG suppression without increasing LDL cholesterol like Batoclimab does. Financial caution is advised as Immunovant's cash runway only extends for 12 months, likely necessitating IMV...

Presents Current Treatment Practices, Emerging Drugs, Market Share of Individual Therapies, and FcRn Inhibitor Market Size from 2020 to 2034 Presents Current Treatment Practices, Emerging Drugs, Market Share of Individual Therapies, and FcRn Inhibitor Market Size from 2020 to 2034

NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported development updates and financial results for its fiscal second quarter ended September 30, 2024.

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that data from the Phase 2a trial of batoclimab in Graves' disease will be the subject of an oral presentation of a late-breaking abstract accepted for the 2024 American Thyroid Association (ATA) ...

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported positive results from the Phase 2a trial of batoclimab in Graves' Disease. Immunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among...